Views: 89
– O desenvolvimento da vacina para o COVID19 é o marco da corrida entre laboratórios ao redor do mundo. A meta dessa corrida é salvar vidas. Veja aqui quais são as vacinas e quais os laboratórios estão realizando os testes.
Minapim por Hernan Valenzuela: Tudo vai passar, a solução está a caminho, vamos continuar cuidando da família e de nós mesmos, a vacina para o COVID19 já está em teste, e será oferecida para nossa proteção. É bom ficar longe da media que busca apavorar o leitor, manter-se positivo e cuidadoso é a estratégia certa.
Devido a urgência e para acelerar o desenvolvimento e a distribuição da vacina para o COVID19, foram estabelecidos diferentes consórcios internacionais, envolvendo investimentos de Bilhões de Dólares. Esse desenvolvimento simultâneo provavelmente deixará alguns de fora da corrida, antes de atingir os estágios necessários para a aprovação.
Vários tipos de vacina estão sendo pesquisados e testados, alguns tradicionais outros experimentais. Entre vantagens e desvantagens, é provável que seja necessário recorrer a mais de uma vacina para proteger a população mundial.
No dia que este artigo está sendo escrito, já tem 15 países desenvolvendo 194 vacinas, usando 9 tecnologias diferentes, sendo que 17 já em testes clínicos.
Em paralelo estão em curso 271 tratamentos experimentais para a doença.
Tratamentos fornecem ferramentas para ajudar os pacientes enquanto uma vacina é desenvolvida. Tratamentos potenciais incluem medicamentos atualmente utilizados ou sendo estudados para tratar de outras doenças, isto é, trabalhos anteriores estão sendo “reaproveitados”, identificados ou projetados para tratar o COVID-19.
O processo de desenvolvimento de uma vacina, em condições normais leva uma década, mas devido a urgência e letalidade da Pandemia do COVID-19 os prazos estão sendo compactados.
Como funcionam as vacinas
Tradicionalmente são injetados germes, as vacinas contêm os mesmos germes, mortos ou enfraquecidos, ou parte do germe que causa a doença.
Depois que a vacina está no organismo, estimula o sistema imunológico a produzir anticorpos, como se tivesse sido exposto ao germe. A pessoa então desenvolve imunidade a essa doença sem precisar obtê-la primeiro. A vacina não cura a doença, ela impede que ocorra.
Se estima que o processo do desenvolvimento até o uso público seja de 12 a 18 meses a partir de janeiro de 2020, a partir da publicação da sequência genética do vírus que causa o COVID-19.
O processo de desenvolvimento tem quatro fases antes da etapa final de aprovação.
São estes os diferentes tipos de vacina que estão em teste:
Inactivated Virus / Live Attenuated Virus/ Protein Subunit /Dna-Based / Rna-Based/ Replicating Viral Vector / Non-Replicating Viral Vector/ Virus-Like Particle
Até o dia de hoje o vírus já tinha infectado 13 milhões de pessoas e 580 mil tinham perdido a luta para o vírus. A esperança vem daquelas vacinas que já estão em teste de campo com Humanos:
Reino Unido
Universidade de Oxford e Astrazeneca, AZD1222 –
Segundo especialistas esta vacina gera anticorpos contra a proteína spike do SARS-CoV-2, que forma a coroa do vírus. A proteína Spike tem um papel crucial na infecção, penetrando nas células humanas. O AZD1222 teve sucesso nos testes do Reino Unido na Fase 2 de ensaios clínicos. Da terceira participam o Brasil e na África do Sul.
China
Sinovac Biotech é o teste que também está na fase Humana, Ad5-nCoV, desenvolvido pela CanSino Biologics junto com a Academia Chinesa de Ciências Médicas Militares. Esta vacina tem como base a tecnologia usada para curar o Ebola.
CanSino Biologics Inc, – China.
O terceiro teste em andamento é o CoronaVac, sendo desenvolvido pela Sinovac, empresa chinesa de capital privado, que já passou para a terceira fase de ensaios clínicos. O Sinovac também iniciou a terceira fase de testes na China e no Brasil em junho.
Veja aqui uma relação das principais vacinas de diferentes tipos que estão em teste.
Inactivated Virus
- Sinovac/ Instituto Butantan Inactivated (Inactivated+Alum); Coronavac (Formerly Picovacc) Related use: Same platform as vaccine candidates for SARS Anticipated Next Steps Phase III enrolling in Brazil in July 2020; Phase II started in June 2020; preliminary results from Phase I/II trials released June 2020 Clinical Trials for COVID-19 NCT04456595, NCT04352608, NCT04383574
- Institute of Medical biology, Chinese Academy of Medical Sciences inactivated Anticipated Next Steps Phase II began June 2020 Clinical Trials for COVID-19 NCT04412538
- Wuhan Institute of Biological products/ sinopharm inactivated Anticipated Next Steps Early Phase I/II trial results released June 2020 Clinical Trials for COVID-19 ChiCTR2000031809
- Beijing Institute of Biological Products/ Sinopharm inactivated Anticipated Next Steps In Phase II, June 2020 Clinical Trials for COVID-19 ChiCTR2000032459
- Bharat Biotech whole-virion inactivated
- Selcuk University inactivated
- Km Biologics inactivated (inactivated + alum)
- Valneva/ Dynavax inactivated (inactivated + cpg 1018), vla2001
- National Research Centre, Egypt inactivated whole virus
- Sinovac/ Dynavax inactivated (inactivated + cpg 1018)
- Osaka University / Biken / Nibiohn inactivated
- Research Institute for Biological Safety problems, Republic of Kazakhstan inactivated
- Beijing Minhai Biotechnology co., ltd. inactivated
Protein Subunit
- Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma protein subunit; recombinant spike protein with advax adjuvant (covax-19) related use n/a anticipated next steps phase i trial started july 2020 clinical trials for covid-19 nct04453852
- Novavax/ Emergent Biosolutions/ Praha Vaccines/Serum Institute of India/ agc Biologics protein subunit; full-length recombinant sars cov-2 glycoprotein nanoparticle vaccine adjuvanted with matrix m (nvx-cov2373) Funder: coalition for epidemic preparedness (cepi)/ us department of defense related use: same platform as vaccine candidates for rsv, cchf, hpv, vzv, ebov anticipated next steps: will join us operation warp speed vaccine trials, phase iii trial to start in fall 2020; phase i/ii started may 2020; top-line data expected july 2020 clinical trials for covid-19 nct04368988
- Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese academy of Sciences adjuvanted recombinant protein (rbd-dimer) related use same platform as vaccine candidates for mers anticipated next steps phase ii to start as early as july 2020; phase i preliminary results expected in september 2020; received approval to launch clinical trials in china in june 2020 clinical trials for covid-19 nct04445194
- Innomedica protein subunit, talicovax19
- Bogazici University peptide + novel adjuvant
- Izmir Biomedicine and Genome Center recombinant s protein
- University of Virginia subunit intranasal liposomal formulation with gla/3m052 adjs.
- Immunoprecise/ Litevax bv spike-based (epitope screening)
- National Research Centre, Egypt protein subunit s, n, m & s1 protein
- Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria subunit
- Baiya Phytopharm/ Chula Vaccine Research Center plant-based subunit (rbd-fc + adjuvant)
- Imv, inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada protein subunit; dpx-covid-19, protein subunit, peptide antigens formulated in lnp
- Intravacc/Epivax outer membrane vesicle (omv)-subunit x
- University of San Martin and Conicet, Argentina protein subunit
- Visheng Biopharma protein subunit, recombinant protein
- Wrair / Usamriid protein subunit; s protein
- Verndari/ University of California, Davis spike protein; vaxipatch microneedle array dermal patch
- Vabiotech protein subunit, recombinant s protein in ic-bevs
- Vaxil Bio protein subunit; peptide
- University of Alberta protein subunit; spike based
- University of California, San Diego protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch
- St. Petersburg Scientific Research Institute of Vaccines and Serums protein subunit, recombinant protein, nanoparticles (based on s-protein and other epitopes)
- Quadram Institute Biosciences omv-based vaccine
- Mogam Institute for Biomedical Research, GC Pharma protein subunit
- Lakepharma, Inc. protein subunit, nanoparticle vaccine
- Lomonosov Moscow State University structurally modified spherical particles of the tobacco mosaic virus (tmv)
- Neovii/Tel Aviv University rbd-based
- Medigen Vaccine Biologics Corp/ Niaid/ Dynavax s-2 p protein + cpg 1018
- National Institute of Infectious Disease, Japan protein subunit, s protein + adjuvant
- Osaka University / Biken / National Institutes of Biomedical Innovation, Japan protein subunit, vlp-recombinant protein + adjuvant
- Kentucky Bioprocessing (British American Tobacco) rbd-based
- Oncogen protein subunit, synthetic long peptide vaccine candidate for s and m proteins
- Migal Galilee Research Institute protein subunit; oral e. coli-based protein expression system of s and n proteins
- Pds Biotechnology pds-0203; versamune t-cell activating technology
- Max-Planck Institute of Colloids and Interfaces targeted (langerhans cell specific) protein subunit; spike based
- Intravacc/Epivax outer membrane vesicle (omv)-peptide
- Innovax / Xiamen University / GSK protein subunit; covid-19 xwg-03 truncated spike proteins
- Ibio / CC-Pharming protein subunit; subunit protein, plant produced
- Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing protein subunit (gp-96 backbone)
- Fbri Src vb Vector, Rospotrebnadzor, Koltsovo protein subunit; subunit vaccine
- Expres2ion protein subunit, drosophila s2 insect cell expression system vlps
- Fbri Src vb Vector, Rospotrebnadzor, Koltsovo protein subunit; peptide vaccine
- Generex / Epivax protein subunit; ii-key peptide
- Flow Pharma protein subunit, peptide
- Epivax / University of Georgia protein subunit; s protein
- Epivax protein subunit epv-cov-19
- Anygo Technology protein subunit, recombinant s1-fc fusion protein
- Biomvis Srl/ University of Trento omv-based vaccine
- Baylor College of Medicine protein subunit; s1 or rbd protein
- Biological e Ltd protein subunit; adjuvanted protein subunit (rbd)
- Applied Biotechnology Institute, Inc. orally delivered, heat stable subunit
- Axon Neuroscience SE peptides derived from spike protein
- Chulalongkorn University/ GPO, Thailand rbd protein fused with fc of igg + adjuvant
- Aj Vaccines protein subunit; s protein
- University of Pittsburgh pittcovacc, protein subunit, microneedle arrays s1 subunit
- University of Cambridge / Diosynvax protein subunit; s protein
- Sanofi Pasteur / GSK protein subunit; s protein, baculovirus production
- Vido-Intervac, University of Saskatchewan protein subunit, adjuvanted microsphere peptide
- Prevent-Ncov CVonsortium (Adaptvac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, Expres2ion Biotechnologies, Wageningen University)/ Bavarian Nordic protein subunit, capsid-like particle (clp)
- Umn Pharma (Shionogi) protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology
Dna-Based
- Inovio Pharmaceuticals/Beijing Advaccine Biotechnology/Vgxi Inc./ Richter-Helm Biologics/Ology Bioservices dna plasmid vaccine with electroporation; ino-4800 Funder: Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense Related use: Same platform as multiple vaccine candidates Anticipated Next Steps:Phase I initial data released June 30, 2020; Phase II/III trials start July/August 2020 Clinical Trials for COVID-19: NCT04336410, NCT04447781
- Genexine Consortium (Gennbio, International Vaccine Institute, Korea Advanced Institute Of Science And Technology (Kaist), Pohang University Of Science And Technology (Postech)/ Binex dna vaccine (gx-19) Related use N/A Anticipated Next Steps: Phase I to start in July 2020 Clinical Trials for COVID-19 NCT04445389
- Statens Serum Institute, Denmark Dna Plasmid, Covaxix
- Osaka University/ Anges/ Takara Bio/ Cytiva Dna Plasmid
- Ege University DNA
- Scancell/ University Of Nottingham/ Nottingham Trent University Dna Plasmid Vaccine Rbd&N
- Mediphage Bioceuticals/ University Of Waterloo Msdna Vaccine
- Zydus Cadila Healthcare Limited Dna Plasmid
- Entos Pharmaceuticals/ Cytiva Dna; Covigenix
- National Research Centre, Egypt Dna Plasmid Vaccine S, S1, S2, Rbd & N
- Chula Vaccine Research Center Dna With Electroporation
- Takis/ Applied Dna Sciences/ Evvivax Dna
- Symvivo Bactrl-Spike
- Immunomic Therapeutics / Epivax / Pharmajet Dna Plasmid, Needle-Free Delivery
- Bionet Asia Dna
- Opencorona – Cobra Biologics / Karolinska Institute Dna With Electroporation
Rna-Based
- Moderna/ Niaid/ Lonza/ Catalent/ Rovi Rna; Lnp-Encapsulated Mrna (Mrna 1273) Funder : Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA) Related use: Same platform as vaccine candidates for multiple candidates Anticipated Next Steps: Will join US Operation Warp Speed vaccine Phase III trials in July 2020; Completed enrollment for both cohorts of the Phase II study in early July 2020; FDA granted fast track designation May 2020 Clinical Trials for COVID-19: NCT04283461, NCT04405076
- Biontech/ Fosun Pharma/ Pfizer 3 Lnp-Mrnas; Bnt162 Related use N/A Anticipated Next Steps: FDA granted Fast Track designation for two BNT162 candidates (BNT162b1 and BNT162b2); Phase IIb/III trial may start as early as July 2020 (not participating in the NIH testing program); Phase I/II started April 2020; first data released July 1, 2020 Clinical Trials for COVID-19: EudraCT 2020-001038-36, NCT04368728
- Curevac Rna; Mrna Funder: Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA); German Government; European Investment Bank (EIB) Related use: Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV Anticipated Next Steps: Start Phase I/IIa trial June 2020 Clinical Trials for COVID-19 : NCT04449276
- Imperial College London/ Vacequity Global Health Rna; Lnp-Ncovsarna Funder: UK Government Related use: Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV Anticipated Next Steps: Phase I/II trial started June 2020 Clinical Trials for COVID-19: ISRCTN17072692
- People’s Liberation Army (Pla) Academy Of Military Sciences/ Walvax Biotech Mrna
- Selcuk University Mrna
- Chula Vaccine Research Center/University Of Pennsylvania Lnp-Mrna
- Chimeron Bio/ George Mason University’s National Center For Biodefense And Infectious Disease Self Amplifying Rna, Self-Assembling Delivery System
- Arcturus/Duke-Nus/ Catalent Lunar-Cov19; Rna; Mrna
- Ziphius Therapeutics/ Ghent University Rna; Zip-1642, Vaccine Consists Of A Combination Of Mrna Molecules, Encoding Multiple Sars-Cov-2 Antigens
- University of Tokyo / Daiichi-Sankyo Rna; lnp-encapsulated mrna
- Rnaimmune, Inc. Rna; Several Mrna Candidates
- Max Planck Institute Of Colloids And Interfaces Mrna In Targeted Lpns (Langerhans Cell Specific)
- Geneone Life Science / Houston Methodist Rna
- Greenlight Biosciences Mrna
- Fudan University / Shanghai Jiaotong University / Rnacure Biopharma Rna; Lnp-Encapsulated Mrna Cocktail Encoding Rbd
- Idibaps- Hospital Clinic, Spain Mrna
- Fudan University / Shanghai Jiaotong University / Rnacure Biopharma Rna; Lnp-Encapsulated Mrna Cocktail Encoding Vlp
- China Cdc / Tongji University / Stermina Rna; Mrna
- Fbri Src Vb Vector, Rospotrebnadzor, Koltsovo Rna; Mrna
- Centro Nacional Biotecnologia (Cnb-Csic), Spain Rna; Replicating Defective Sars-Cov-2 Derived Rnas
- Cansino Biologics/Precision Nanosystems Rna; Mrna Lipid Nanoparticle (Mrna-Lnp)
- Sanofi Pasteur / Translate Bio Lnp-Mrna
- Etherna Immunotherapies / Epivax/ Nexelis/ Reprocell / Centre For The Evaluation Of Vaccination Of The University Of Antwerp Rna; Mrna In An Intranasal Delivery System (Cross-Strain Protective Cov-2 Mrna) Vaccine For High-Risk Populations
- Biocad Rna; Liposome-Encapsulated Mrna
Replicating Viral Vector
- Zydus Cadila Healthcare Limited Replicating Viral Vector; Measles Vector
- Dzif – German Center For Infection Research/ Canvirex Ag
- Measles Virus (S, N Targets)
- Israel Institute For Biological Research/ Weizmann Institute Of Science Vsv-S
- The University Of Hong Kong Replicating Viral Vector, Influenza Vector Expressing Rbd
- The Lancaster University, Uk Avian Paramyxovirus Vector (Apmv)
- University Of Western Ontario Replicating Viral Vector; Vsv-S
- Tonix Pharma / Southern Research Replicating Viral Vector; Horsepox Vector Expressing S Protein; Tnx-1800
- Ku Leuven Replicating Viral Vector; Yf17d Vector
- Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ. Newcastle Disease Virus Vector (Ndv-Sars-Cov-2/Spike)
- Fbri Src Vb Vector, Rospotrebnadzor, Koltsovo Replicating Viral Vector; Measles Vector
- Fundacao Oswaldo Cruz And Instituto Buntantan Attenuated Influenza Expressing An Antigenic Portion Of The Spike Protein
- Fbri Src Vb Vector, Rospotrebnadzor, Koltsovo Replicating Viral Vector; Vsv Vector
- Biocad / Iem Replicating Viral Vector, Live Viral Vectored Vaccine Based On Attenuated Influenza Virus Backbone (Intranasal)
- Fbri Src Vb Vector, Rospotrebnadzor, Koltsovo Replicating Viral Vector, Recombinant Vaccine Based On Influenza A Virus, For The Prevention Of Covid-19 (Intranasal)
- University Of Wisconsin-Madison / Flugen/ Bharat Biotech M2-Deficient Single Replication (M2sr) Influenza Vector
- Iavi/ Merck Replicating Viral Vector, Replication-Competent Vsv Chimeric Virus Technology (Vsvdeltag) Delivering The Sars-Cov-2 Spike (S) Glycoprotein
- Institut Pasteur / Themis / University Of Pittsburgh / Merck Replicating Viral Vector; Measles Vector
Non-Replicating Viral Vector
- Consortium Of The Jenner Institute, Oxford Biomedica, University Of Oxford, Vaccines Manufacturing And Innovation Centre, Pall Life Sciences, Cobra Biologics, Halixbv, Advent S.R.L., Merck Kgaa, The Serum Institute, Vaccitech, And Astrazeneca Non-Replicating Viral Vector; Azd 1222 (Formerly Chadox1)
- Cansino Biologics/Beijing Institute Of Biotechnology/ Canada’s National Research Council Non-Replicating Viral Vector; Adenovirus Type 5 Vector (Ad5-Ncov)
- Gamaleya Research Institute Adeno-Based
- Ankara University Adenovirus-Based
- Id Pharma Sendai Virus Vector
- Dzif – German Center For Infection Research/ Idt Biologika Gmbh Non-Replicating Viral Vector; Mva-S Encoded
- Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent Biosolutions/ Catalent Ad26.Cov2-S, Non Replicating Viral Vector; Ad26 (Alone Or With Mva Boost)
- National Research Centre, Egypt Influenza A H1n1 Vector
- Immunitybio/ Nantkwest Non-Replicating Viral Vector; [E1-, E2b-, E3-] Had5-Covid19-Spike/Nucleocapsid
- Valo Therapeutics Ltd Adenovirus-Based + Hla-Matched Peptides (Pan-Corona)
- University Of Manitoba Non-Replicating Viral Vector; Dendritic Cell-Based Vaccine
- University Of Georgia/ University Of Iowa Non-Replicating Viral Vector; Parainfluenza Virus 5 (Piv5)-Based Vaccine Expressing The Spike Protein
- Stabilitech Biopharma Ltd Oral Ad5 S
- National Center For Genetic Engineering And Biotechnology (Biotec)/ Gpo, Thailand Inactivated Flu-Based Sars-Cov2 Vaccine + Adjuvant
- Idibaps- Hospital Clinic, Spain Mva-S
- Geovax / Bravovax Non-Replicating Viral Vector; Mva Encoded Vlp
- Greffex Non-Replicating Viral Vector; Ad5 S (Grevax™ Platform)
- Centro Nacional Biotecnologia (Cnb-Csic), Spain Non-Replicating Viral Vector, Mva Expressing Structural Proteins
- Bharat Biotech/ Thomas Jefferson University Recombinant Deactivated Rabies Virus Containing S1
- Vaxart / Emergent Biosolutions Non-Replicating Viral Vector; Oral Vaccine Platform
- Reithera/ Leukocare/ Univercells Non-Replicating Viral Vector; Replication Defective Simian Adenovirus (Grad) Encoding Sars-Cov-2 S
- Grousbeck Gene Therapy Center At Mass. Eye And Ear/ Avexis, A Novartis Company/ Viralgen/ Aldevron/ Catalent/ Penn Medicine Aavcovid, Adeno-Associated Viral Vector (Aav), Spike Protein
- Altimmune / University Of Alabama At Birmingham Adcovid; Single-Dose, Intranasal Vaccine; Non Replicating Viral Vector; Adenovirus-Based Nasovax Expressing Spike Protein
Virus-Like Particle
- Medicago Inc./ Gsk Vlp (Covlp)+ Adjuvant
- Medicago Inc. Vlp; Plant-Derived Vlp Adjuvanted With Gsk Or Dynavax Adjs.
- Medicago Inc./ Dynavax Vlp (Covlp)+ Adjuvant (Cpg 1018)
- Middle East Technical University Vlp
- Osivax Vlp (Covid-19 And Sars1)
- Doherty Institute Vlp; Unknown
- Vbi Vaccines / National Research Council Of Canada Enveloped Virus-Like Particle (Evlp): Pan-Coronavirus Vacina Candidate, Targeting Covid-19, Sars, And Mers, Spike Protein
- Mahidol University/ The Government Pharmaceutical Organization (Gpo)/
- Siriraj Hospital Vlp + Adjuvant
- Irsicaixa Aids Research/ Irta-Cresa/ Barcelona Supercomputing Centre/
- Grifols S Protein Integrated In Hiv Vlps
- University Of Sao Paulo Vlps Peptides/Whole Virus
- Saiba Gmbh Vlp; Virus-Like Particle, Based On Rbd Displayed On Virus-Like Particle
- Navarrabiomed, Oncoimmunology Group Virus-Like Particles, Lentivirus, And Baculovirus Vehicles
- Artes Biotechnology Vlp; Evlp
- Imophoron Ltd / Bristol University’s Max Planck Centre Vlp; Addomertm Multiepitope Display
Live Attenuated Virus
- Mehmet Ali Aydinlar University/ Acibadem Labmed Health Services a.s. codon deoptimized live attenuated vacina Anticipated Next Steps Unknown Clinical Trials for COVID-19 N/A
- Meissa Vaccines mv-014-210 Related use Same platform as vaccine candidates for RSV Anticipated Next Steps Start Phase 1 beginning of 2021 Clinical Trials for COVID-19 N/A
- Indian Immunologicals Ltd/ Griffith University codon deoptimized live attenuated virus Related use N/A Anticipated Next Steps Unknown Clinical Trials for COVID-19 N/A
- Codagenix / Serum Institute of India codon deoptimized live attenuated virus Related use Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV Anticipated Next Steps Animal data in summer 2020 Clinical Trials for COVID-19 N/A
Source: Milken Institute
Artigo Relacionado: Desenvolvimento da vacina contra o coronavírus baseada em mRNA da CureVac